Cost–effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation

Received 5 March 2002; accepted 23 July 2002.

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with a large economic and social burden. Few economic studies have examined the benefits of inhaled therapy for patients with COPD. This 16-week study examined the cost–effectiveness of salmeterol in this patient group. Patients with a history of COPD were randomised to treatment with salmetrol 50mcg (229 patients) or placebo (227 patients) twice daily, administered by metered-dose inhaler in addition to normal therapy. Forced expiratory volume (FEV1) was measured and patients recorded the impact of their symptoms in a daily diary. Health status was assessed using the St George's Respiratory Questionnaire. A significantly higher proportion of salmeterol-treated patients had an increase of >15% in FEV1. Salmeterol patients had a higher mean proportion of symptom-free days and nights than those in the placebo group. More salmeterol patients had a clinically significant improvement in health status. Total healthcare costs were increased in the salmeterol group, but hospital and GP visit costs and concurrent COPD medication costs were lower. The reduction in hospital costs was sufficient to offset a substantial portion of the acquisition cost of salmeterol. Addition of salmeterol to COPD patients' current therapy improved lung function, health status at the expense of a modest increase in costs compared with usual therapy.

Keywords: salmeterol, chronic obstructive pulmonary disorder, cost–effectiveness analysis, quality of life.

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

REFERENCES

1. 1 Am J Respir Crit Care Med. 1995;152:S77–S120.

2. 2 Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet. 1998;352:467–473. Abstract | Full Text | Full-Text PDF (91 KB) | CrossRef

3. 3 Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am. 1996;80:501–522. MEDLINE

4. 4 Pelletier-Fleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD patients with long term oxygen therapy in a French population. Chest. 1996;100:411–416.

5. 5 Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis. 1989;140:S27–S34. MEDLINE

6. 6 Donohue W, Plummer A. Magnitude and usage of home oxygen therapy in the United States. Chest. 1995;107:301–302. MEDLINE | CrossRef

7. 7 Turner-Warwick M, Hudson ME, Corrin B. Clinical Atlas of Respiratory Diseases. London: Gower Medical Publishing; 1990;.

8. 8 Mahler DA, Donahue JF, Barbee RA. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957–965. MEDLINE | CrossRef

9. 9 Jones PW, Bosh T. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289.

10. 10 Boyd G, Morice AH, Pounsford JC. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997;10:815–821. MEDLINE

11. 11 Jones PW, Quirck FH, Baveystock CM. The St. Respir Med. 1991;85:25–31. CrossRef

12. 12 Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation — the St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327. MEDLINE

13. 13 Desgagne A, Castilloux AM, Angers J-F, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. PharmacoEconomics. 1998;13:487–497. MEDLINE | CrossRef

14. 14 Rutten-Van Molken MP, Van Doorslaer EK, Jansen MC. Cost and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982.

15. 15 Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinaoate: an analysis of outcomes and cost–effectiveness using a primary care database. Resp Med. 1998;92:1302–1304.

16. 16 Lorenzo G, Morici G, Drago A. Efficacy, tolerability and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther. 1998;20:1130–1148. MEDLINE | CrossRef

a St George's Hospital Medical School, London, U.K.

b GlaxoSmithKline R&D, Greenford, Middlesex, U.K.

f1 Correspondence to: Professor Paul W Jones, Division of Physiological Medicine, St. George's Hospital Medical School, Cramer Terrace, London SW17 ORE, U.K. Fax: +44 20 8725 5955; E-mail: pjones@sghms.ac.uk

PII: S0954-6111(02)91425-3

doi:10.1053/rmed.2002.1425

4 of 18